Clinical trial

Investigating Dupilumab's Effect in Asthma by Genotype

NCT03694158

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-09-08

PhasePHASE4

Study timeline

Study start (actual)2021-09-08Date precision: day

Registry last updated2026-02-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Asthmaunresolved

Interventions

DupilumabDRUG · verified · RxNorm: dupilumab

Sponsors & collaborators

Boston Children's Hospitallead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)collaborator

Regeneron Pharmaceuticalscollaborator

HealthBeacon Plccollaborator

Merck Sharp & Dohme LLCcollaborator

Sanoficollaborator

Mapped research locations

BostonMassachusetts, United States2 PhiladelphiaPennsylvania, United States1 ClevelandOhio, United States1 DetroitMichigan, United States1 The BronxNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03694158 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.